# US 12,110,328 B2 · Single domain antibodies targeting CD1d > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,110,328 B2 - Document ID: US12110328B2 - Status: Granted - Kind: B2 - Application number: 18/161,163 - Filed: 2023-01-30 - Published: 2024-02-29 - Granted: 2024-10-08 - Earliest claimed: 2015-01-27 - Assignees: Lava Therapeutics N.V. - Applicants: Lava Therapeutics N.V. - Inventors: Johannes Jelle Van Der Vliet; Tanja Denise De Gruijl; Hendrik Marinus Willem Verheul; Renée Cornelia Gerarda De Bruin; Roeland Lameris - Web page: https://patentgrep.com/patent/US12110328B2 ## CPC - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex} - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 11/06: Antiasthmatics - A61P 17/06: Antipsoriatics - A61P 21/04: for myasthenia gravis - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/04: Immunostimulants - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C07K 16/30: from tumour cells - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® - C07K 2317/75: Agonist effect on antigen - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies. ## Claims ### Claim 1 A compound comprising a single domain antibody that binds to CD1d, comprising a complementarity determining region (CDR)-1, CDR2, and CDR3, wherein; a. the CDR1 comprises an amino acid sequence of SEQ ID NO: 24, the CDR2 comprises an amino acid of SEQ ID NO: 45, and the CDR3 comprises an amino acid of SEQ ID NO: 66; b. the CDR1 comprises an amino acid sequence of SEQ ID NO: 26, the CDR2 comprises an amino acid of SEQ ID NO: 47, and the CDR3 comprises an amino acid of SEQ ID NO: 68; c. the CDR1 comprises an amino acid sequence of SEQ ID NO: 27, the CDR2 comprises an amino acid of SEQ ID NO: 48, and the CDR3 comprises an amino acid of SEQ ID NO: 69; d. the CDR1 comprises an amino acid sequence of SEQ ID NO: 29, the CDR2 comprises an amino acid of SEQ ID NO: 50, and the CDR3 comprises an amino acid of SEQ ID NO: 71; or e. the CDR1 comprises an amino acid sequence of SEQ ID NO: 37, the CDR2 comprises an amino acid of SEQ ID NO: 58, and the CDR3 comprises an amino acid of SEQ ID NO: 79. ### Claim 2 (depends on 1) The compound of claim 1, wherein the single domain antibody binds to human CD1d but not to human CD1a human CD1b and/or human CD1c. ### Claim 3 (depends on 1) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. ### Claim 4 (depends on 1) A nucleotide sequence encoding the compound of claim 1. ### Claim 5 (depends on 1) An isolated host cell or non-human organism comprising a nucleotide sequence encoding the compound of claim 1. ### Claim 6 (depends on 1) The compound of claim 1, further comprising an additional single domain antibody. ### Claim 7 (depends on 1) The compound of claim 1, wherein the compound is a bispecific or multispecific compound. ### Claim 8 (depends on 1) The compound of claim 1, wherein the compound is linked to an antibody. ### Claim 9 A compound comprising a single domain antibody that binds to CD1d, comprising a complementarity determining region (CDR)-1, CDR2, and CDR3, wherein the CDR1 comprises SEQ ID NO: 37, the CDR2 comprises SEQ ID NO: 58, and the CDR3 comprises SEQ ID NO: 79. ### Claim 10 (depends on 9) The compound of claim 9, further comprising an additional single domain antibody. ### Claim 11 (depends on 9) The compound of claim 9, wherein the compound is a bispecific or multispecific compound. ### Claim 12 (depends on 9) The compound of claim 9, wherein the compound is linked to an antibody. ### Claim 13 (depends on 9) A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier. ### Claim 14 (depends on 9) A nucleotide sequence encoding the compound of claim 9. ### Claim 15 (depends on 9) An isolated host cell or non-human organism comprising a nucleotide sequence encoding the compound of claim 9.